An observational study in Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL), sponsored by Cellect Biotechnology. Status unknown at 1 site in Israel. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-11-26.
Sponsored by Cellect Biotechnology · Observational
This is a non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01. Up to 12 subjects who completed ApoGraft-01 study will be offered to participate in this follow-up study.
Subjects who completed ApoGraft-01 study and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend in-clinic visits up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence), physical examination, safety laboratory and concomitant medication use.
Up to 12 subjects who completed ApoGraft-01 study will be offered to participate in this follow-up study. Subjects must have had one of the Hemato-Oncology Diseases to enroll into ApoGraft-01:
Inclusion Criteria:
Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01
Other: non intervational
Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
Also known as: ApoGraft follow up
Incidence, grade and stage of acute GvHD and chronic GvHD
GVHD will be assessed according to NIH criteria 2005; current and maximal score at each visit.
Time frame: 18 months
Non-relapse-related mortality
Time frame: 18 months
Proportion of subjects with disease relapse/recurrence
Time frame: 18 months
Proportion of subjects with relapse free and overall survival
Time frame: 18 months
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cellect Biotechnology